Highlights
– Amycretin, a novel unimolecular GLP-1 and amylin receptor agonist, achieved up to 24.3% weight loss over 36 weeks in overweight or obese adults.
– The safety profile was consistent with known GLP-1 and amylin agonists, primarily involving mild-to-moderate gastrointestinal events.
– The study supports further investigation of amycretin as a potential anti-obesity therapy, reflecting a new direction in incretin-based pharmacotherapy.
– This trial adds to the dynamic landscape of multi-agonist therapies in metabolic disease management.
